Jun 2026 (Q2 FY26) — Aug 6, 2026
Tarsus Pharmaceuticals Q2 FY26 — Record XDEMVY Sales and Strategic Acquisition of Alkeus Pharmaceuticals
Read the full callTarsus Pharmaceuticals (TARS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Tarsus Pharmaceuticals earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 174 | +69.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -11.4 | +10.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -18.6 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$69.5 +2.10% · +$1.43
Performance −4.7% 1Y
1Y: $72.93 on 17 Oct 2025 → $69.5. High $90.78 (4 Sept 2026), low $56.11 (14 Jul 2026).
- Previous close
- $68.07
- 52-week range
- $56.11 – $90.78
- One year
- −2.37%
Overview
- Symbol
- TARS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Tarsus Pharmaceuticals earnings calls (TARS)
Financials
What the filings say
Net profit, year on year: +9% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 48 | 66 | 78 | 103 | 119 | 152 | 162 | 174 |
| Expenses | 73 | 91 | 105 | 125 | 133 | 160 | 168 | 194 |
| Operating profit | -25 | -24 | -26 | -22 | -15 | -8 | -6 | -20 |
| Operating margin | −52.3% | −36.8% | −33.5% | −21.6% | −12.2% | −5.3% | −3.8% | −11.4% |
| Other income | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 4 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Net profit | -23 | -23 | -25 | -20 | -13 | -8 | -7 | -19 |
| EPS ($ per share) | -0.61 | — | -0.64 | -0.48 | -0.30 | — | -0.16 | -0.43 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | — | -6 | -33 | -47 | -109 | -245 | -360 | -427 |
| Total liabilities | — | 1 | 6 | 12 | 35 | 69 | 152 | 219 |
| Fixed assets | — | 0 | 1 | 1 | 1 | 1 | 2 | 12 |
| Investments | — | — | 0 | 0 | 145 | 2 | 197 | 234 |
| Total assets | — | 58 | 172 | 179 | 228 | 265 | 377 | 562 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -4 | -21 | 4 | -49 | -117 | -83 | -12 |
| Cash from investing | -0 | -0 | -1 | -145 | 141 | -199 | -42 |
| Cash from financing | 59 | 132 | 0 | 94 | 130 | 155 | 143 |
| Net cash flow | 56 | 110 | 3 | -100 | 153 | -128 | 89 |
| Capital expenditure | -0 | -0 | -1 | -1 | -2 | -2 | -10 |
| Free cash flow | -4 | -22 | 3 | -50 | -119 | -85 | -22 |
Insider filings
82 filings between Dec 4, 2025 and Sep 15, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$19.96M
59 sales by 9 insiders
61% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 20
- Option exercise — converted options into shares
Also filed: 3 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Azamian Bobak R. | — | $5.18M | Sep 4, 2026 |
| LINK WILLIAM J PHD | — | $4.48M | Sep 15, 2026 |
| Whitfield Dianne C. | — | $2.69M | Mar 19, 2026 |
| Lin Elizabeth Yeu | — | $2.36M | Sep 4, 2026 |
| Neervannan Seshadri | — | $2.00M | Sep 4, 2026 |
| Farrow Jeffrey S | — | $1.32M | Jun 16, 2026 |
| Mottiwala Aziz | — | $892.5K | Mar 19, 2026 |
| Wahl Bryan | — | $850.4K | Mar 19, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 15, 2026 | PYOTT DAVID E I Director | Option exercise | 201 | — |
| Sep 15, 2026 | LINK WILLIAM J PHD Director | Sale 10b5-1 plan | 759 | $60.0K |
| Sep 15, 2026 | LINK WILLIAM J PHD Director | Sale 10b5-1 plan | 66 | $5.3K |
| Sep 15, 2026 | LINK WILLIAM J PHD Director | Sale 10b5-1 plan | 11,675 | $914.5K |
| Sep 15, 2026 | LINK WILLIAM J PHD Director | Option exercise 10b5-1 plan | 201 | — |
| Sep 15, 2026 | YARNO WENDY L Director | Option exercise | 302 | — |
| Sep 4, 2026 | Azamian Bobak R. President/CEO and Board Chair | Sale 10b5-1 plan | 2,900 | $264.7K |
| Sep 4, 2026 | Lin Elizabeth Yeu Chief Medical Officer | Sale 10b5-1 plan | 1,590 | $143.1K |
| Sep 4, 2026 | Lin Elizabeth Yeu Chief Medical Officer | Sale 10b5-1 plan | 5,386 | $484.7K |
| Sep 4, 2026 | Neervannan Seshadri Chief Operating Officer | Sale 10b5-1 plan | 4,564 | $387.9K |
| Sep 4, 2026 | Azamian Bobak R. President/CEO and Board Chair | Sale 10b5-1 plan | 7,100 | $640.9K |
| Sep 4, 2026 | Lin Elizabeth Yeu Chief Medical Officer | Sale 10b5-1 plan | 1,590 | $135.2K |
| Sep 4, 2026 | Lin Elizabeth Yeu Chief Medical Officer | Sale 10b5-1 plan | 5,387 | $457.9K |
| Sep 2, 2026 | Lin Elizabeth Yeu Chief Medical Officer | Sale 10b5-1 plan | 5,387 | $431.0K |
| Sep 2, 2026 | Lin Elizabeth Yeu Chief Medical Officer | Sale 10b5-1 plan | 1,590 | $127.2K |
| Sep 2, 2026 | Azamian Bobak R. President/CEO and Board Chair | Sale 10b5-1 plan | 10,000 | $800.6K |
| Sep 1, 2026 | Lin Elizabeth Yeu Chief Medical Officer | Sale 10b5-1 plan | 4,601 | $339.8K |
| Jun 17, 2026 | Azamian Bobak R. President/CEO and Board Chair | Sale 10b5-1 plan | 4,582 | $280.6K |
| Jun 17, 2026 | Azamian Bobak R. President/CEO and Board Chair | Sale 10b5-1 plan | 5,418 | $334.9K |
| Jun 16, 2026 | Farrow Jeffrey S See Remarks | Sale | 14,396 | $877.4K |
| Jun 15, 2026 | Goodrich Katherine Director | Sale 10b5-1 plan | 2,954 | $183.4K |
| Jun 15, 2026 | LINK WILLIAM J PHD Director | Sale 10b5-1 plan | 10,572 | $655.1K |
| Jun 15, 2026 | Farrow Jeffrey S See Remarks | Option exercise | 27,881 | — |
| Jun 15, 2026 | LINK WILLIAM J PHD Director | Sale 10b5-1 plan | 1,928 | $121.3K |
| Jun 12, 2026 | Goldberg Andrew D. Director | Option exercise | 2,954 | — |
| Jun 12, 2026 | Morrison Scott W Director | Option exercise | 2,954 | — |
| Jun 12, 2026 | Goodrich Katherine Director | Option exercise | 2,954 | — |
| Jun 12, 2026 | YARNO WENDY L Director | Option exercise | 2,954 | — |
| Jun 12, 2026 | CHAUDHURI BHASKAR Director | Option exercise | 2,954 | — |
| Jun 12, 2026 | LINK WILLIAM J PHD Director | Option exercise | 2,954 | — |
| Apr 24, 2026 | PYOTT DAVID E I Director | Option exercise | 1,383 | — |
| Mar 20, 2026 | Neervannan Seshadri Chief Operating Officer | Sale 10b5-1 plan | 2,989 | $199.5K |
| Mar 19, 2026 | Whitfield Dianne C. Chief Human Resources Officer | Sale | 4,174 | $279.7K |
| Mar 19, 2026 | Azamian Bobak R. President/CEO and Board Chair | Sale | 11,964 | $801.6K |
| Mar 19, 2026 | Farrow Jeffrey S See Remarks | Sale | 2,186 | $146.5K |
| Mar 19, 2026 | Neervannan Seshadri Chief Operating Officer | Sale | 4,589 | $307.5K |
| Mar 19, 2026 | Lin Elizabeth Yeu Chief Medical Officer | Sale | 390 | $26.1K |
| Mar 19, 2026 | Mottiwala Aziz Chief Commercial Officer | Sale | 4,440 | $297.5K |
| Mar 19, 2026 | Wahl Bryan General Counsel | Sale | 4,231 | $283.5K |
| Mar 18, 2026 | Whitfield Dianne C. Chief Human Resources Officer | Sale | 4,071 | $279.7K |
| Mar 18, 2026 | Azamian Bobak R. President/CEO and Board Chair | Sale | 11,667 | $801.6K |
| Mar 18, 2026 | Farrow Jeffrey S See Remarks | Sale | 2,133 | $146.6K |
| Mar 18, 2026 | Mottiwala Aziz Chief Commercial Officer | Sale | 4,330 | $297.5K |
| Mar 18, 2026 | Lin Elizabeth Yeu Chief Medical Officer | Sale | 379 | $26.0K |
| Mar 18, 2026 | Wahl Bryan General Counsel | Sale | 4,125 | $283.4K |
| Mar 18, 2026 | Neervannan Seshadri Chief Operating Officer | Sale | 3,610 | $248.0K |
| Mar 17, 2026 | Wahl Bryan General Counsel | Sale | 4,084 | $283.5K |
| Mar 17, 2026 | Whitfield Dianne C. Chief Human Resources Officer | Sale | 4,029 | $279.7K |
| Mar 17, 2026 | Mottiwala Aziz Chief Commercial Officer | Sale | 4,286 | $297.5K |
| Mar 17, 2026 | Azamian Bobak R. President/CEO and Board Chair | Sale | 10,972 | $761.7K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Tarsus Pharmaceuticals, Inc.
Free account. Everything above stays public.
Write why you follow Tarsus Pharmaceuticals, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading